Repare Therapeutics Inc. (NASDAQ:RPTX) Sees Large Decrease in Short Interest

Repare Therapeutics Inc. (NASDAQ:RPTX) was the recipient of a significant decline in short interest in December. As of December 31st, there was short interest totaling 194,336 shares, a decline of 44.8% from the December 15th total of 352,361 shares. Based on an average daily trading volume, of 1,759,426 shares, the short-interest ratio is presently 0.1 days. Approximately 0.5% of the shares of the company are short sold. Approximately 0.5% of the shares of the company are short sold. Based on an average daily trading volume, of 1,759,426 shares, the short-interest ratio is presently 0.1 days.

Analysts Set New Price Targets

A number of equities analysts have recently commented on RPTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Repare Therapeutics in a report on Monday, December 22nd. HC Wainwright dropped their price target on shares of Repare Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a research report on Monday, October 27th. Cowen cut shares of Repare Therapeutics to a “hold” rating in a research note on Monday, November 17th. Wall Street Zen upgraded Repare Therapeutics to a “hold” rating in a research note on Saturday, November 15th. Finally, TD Cowen cut Repare Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, November 17th. One research analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average price target of $3.00.

Repare Therapeutics Trading Up 0.4%

Shares of RPTX stock traded up $0.01 on Friday, reaching $2.58. 533,330 shares of the stock were exchanged, compared to its average volume of 1,477,254. Repare Therapeutics has a one year low of $0.89 and a one year high of $2.66. The stock has a 50 day moving average price of $2.25 and a 200 day moving average price of $1.87.

Repare Therapeutics (NASDAQ:RPTX) last announced its quarterly earnings data on Friday, November 14th. The company reported $0.08 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.43. The firm had revenue of $11.62 million for the quarter, compared to the consensus estimate of $7.50 million. As a group, equities research analysts expect that Repare Therapeutics will post -2.04 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Rangeley Capital LLC bought a new stake in Repare Therapeutics in the second quarter valued at about $494,000. Acadian Asset Management LLC increased its stake in shares of Repare Therapeutics by 35.6% in the 1st quarter. Acadian Asset Management LLC now owns 640,332 shares of the company’s stock valued at $624,000 after acquiring an additional 168,230 shares during the last quarter. Militia Capital Partners LP acquired a new stake in shares of Repare Therapeutics in the 2nd quarter valued at approximately $166,000. Squarepoint Ops LLC bought a new position in Repare Therapeutics during the 3rd quarter worth approximately $115,000. Finally, XTX Topco Ltd acquired a new position in Repare Therapeutics during the second quarter valued at approximately $60,000. 85.09% of the stock is currently owned by institutional investors.

Repare Therapeutics Company Profile

Repare Therapeutics, traded on NASDAQ under the symbol RPTX, is a clinical-stage biopharmaceutical company focused on the discovery and development of precision oncology medicines. The company applies synthetic lethality—a concept whereby cancer-specific genetic vulnerabilities are exploited—to design small-molecule therapies that selectively kill tumor cells while sparing healthy tissue. Repare’s proprietary functional genomics and screening platform integrates CRISPR-based assays and computational biology to systematically uncover novel genetic interactions and therapeutic targets.

At the core of Repare’s approach is its ability to identify and validate DNA damage response (DDR)-related targets.